Skip to main content
Defiance International

Cerebrolysin for the Treatment of Aneurysmal Subarachnoid Hemorrhage in Adults: A Retrospective Chart Review

Human research record. Advances in therapy, 2018.

  • Human
  • 2018

Authorship

Exact sentences from the abstract. No machine-written text is on this page. No person reviewed it.

Source: the abstract of PMID 30414051. Checked Verification: Evidence verified by machine against declared source

This study and its findings belong to the authors cited. Defiance International, a supplier of chemical sequences for research use, keeps this record and makes no claim from its findings.

Verify a lot

Evidence verified by machine against declared source

Open declared source

Key facts

Design
Not reported
System
Human
Scale
Subgroup analyses were performed according to Hunt and Hess grade (good grade ≤ 2, N = 216; poor grade ≥ 3, N = 246) and treatment procedure (clip or coil).
Comparator
Present
Journal
Advances in therapy
Year
2018
PMID
30414051
Verification
Evidence verified by machine against declared source The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Full-text availability
Abstract only

Technical summary

Research question

The aim of this study was to evaluate the effect of Cerebrolysin in patients with aneurysmal SAH.

Study design

One of the limitations of this study was the retrospective design.

Participants or experimental system

Aneurysmal SAH patients who had their aneurysm obliterated at our institution from 2007 to 2016 were retrospectively studied.

Study scale

Subgroup analyses were performed according to Hunt and Hess grade (good grade ≤ 2, N = 216; poor grade ≥ 3, N = 246) and treatment procedure (clip or coil).

Intervention or exposure

Cerebrolysin was administered at daily doses of 30 ml for at least 3 days.

Comparator

Patients received Cerebrolysin treatment or standard care only (control group).

Outcomes examined

SAH sum score (0–30) was calculated as the mean of the Hijdra score, which is the sum of the amount of blood in ten cistern or fissure points (0–3 each).

Key findings

In good-grade patients (N = 216), clinical outcomes and mortality did not differ significantly between the control and Cerebrolysin groups.

Not reported in the declared source: Methods.

Limitations and uncertainty

Further studies are needed to confirm our results.

Cite

Cite the study

Cerebrolysin for the Treatment of Aneurysmal Subarachnoid Hemorrhage in Adults: A Retrospective Chart Review
Y. Park, H. Yi, Kyu-Sun Choi, Young-Jun Lee, Dong-won Kim, S. Kwon. Advances in therapy. 2018. PMID 30414051. DOI 10.1007/s12325-018-0832-8

The study and its abstract belong to their authors and publisher. Cite them for anything the study found.

Report an error

If a sentence on this record does not match the abstract, tell us which one. A report starts an automatic re-check by machine. No person reads the record first.

The form takes a sentence and your note. It asks for no name and no address, and we store neither. Do not put personal details in the note.

The report form runs in the interactive page. Open this record with scripts enabled to send a report.

Corrections on this record

No correction has been recorded for this record.

Method sheet

No machine-drafted summary is published on this record. Any section shown is the abstract’s own sentence, printed as issued.